Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13946505 | 0.88 | CYP2C19 (0.50) | CYP2C19CYP1A2CYP2C9CHRM3KCNN4 | |
| SCHEMBL6481604 | 0.88 | CYP2C19 (0.50) | CYP2C19CYP1A2CYP2C9CHRM3KCNN4 | |
| SCHEMBL6481609 | 0.88 | CYP2C19 (0.50) | CYP2C19CYP1A2CYP2C9CHRM3KCNN4 | |
| SCHEMBL23014014 | 0.86 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP2C9CHRM3KCNN4 | |
| SCHEMBL1292634 | 0.86 | TAAR1 (0.50) | CYP2C19CYP1A2CYP2C9CHRM3KCNN4 | |
| SCHEMBL5950461 | 0.86 | ESR1 (0.46) | CYP2C19CYP1A2CYP2C9CHRM3ALDH1A1 | |
| SCHEMBL28639570 | 0.84 | CYP2C19 (0.47) | CYP2C19CYP1A2CYP2C9CHRM3KCNN4 | |
| SCHEMBL7266181 | 0.84 | CYP1A2 (0.76) | CYP2C19CYP1A2CYP2C9CHRM3SMN1; SMN2 | |
| SCHEMBL7056948 | 0.83 | CYP2C19 (0.57) | CYP2C19CYP1A2CYP2C9CHRM3KCNN4 | |
| SCHEMBL7122087 | 0.83 | CYP1A2 (0.45) | CYP2C19CYP1A2CYP2C9CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312944-A1 | UV-CURABLE COATINGS HAVING HIGH REFRACTIVE INDEX | BASF SE (DE) | 2023-10-05 | — | — | US | claimed |
| EP-4200365-A1 | UV-CURABLE COATINGS HAVING HIGH REFRACTIVE INDEX | BASF SE (DE) | 2023-06-28 | — | — | EP | claimed |
| CN-115867614-A | UV-curable coating with high refractive index | 巴斯夫欧洲公司 | 2023-03-28 | — | — | CN | claimed |
| US-20220389245-A1 | METAL OXIDE NANOPARTICLES | BASF SE (DE) | 2022-12-08 | — | — | US | claimed |
| EP-4031496-A1 | METAL OXIDE NANOPARTICLES | BASF SE (DE) | 2022-07-27 | — | — | EP | claimed |
| CN-114401927-A | Metal oxide nanoparticles | 巴斯夫欧洲公司 | 2022-04-26 | — | — | CN | claimed |
| WO-2022038161-A1 | UV-CURABLE COATINGS HAVING HIGH REFRACTIVE INDEX | BASF SE (DE) | 2022-02-24 | — | — | WO | claimed |
| WO-2021052907-A1 | METAL OXIDE NANOPARTICLES | BASF SE (DE) | 2021-03-25 | — | — | WO | claimed |
| EP-0324980-B1 | Norbornene formulations with longer pot lives and lower molding temperatures | GOODRICH CO B F (US) | 1995-03-29 | — | — | EP | claimed |
| EP-0324979-B1 | Norbornene formulations with longer pot lives | GOODRICH CO B F (US) | 1994-03-23 | — | — | EP | claimed |
| EP-0324979-A2 | Norbornene formulations with longer pot lives | THE B.F. GOODRICH COMPANY (US) | 1989-07-26 | — | — | EP | claimed |
| EP-0324980-A2 | Norbornene formulations with longer pot lives and lower molding temperatures | THE B.F. GOODRICH COMPANY (US) | 1989-07-26 | — | — | EP | claimed |
| EP-3408307-B1 | PROCESS FOR PRODUCING FUNCTIONALIZED ETHYLENE-BASED POLYMERS WITH A LOW GEL CONTENT | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025040241-A1 | A SUNSCREEN COMPOSITION | SYMRISE AG (DE) | 2025-02-27 | — | — | WO | disclosed |
| US-12221458-B2 | Organic borate-based catalyst, method for preparing isobutene oligomer using the same and isobutene oligomer prepared thereby | LG CHEM, LTD. (KR) | 2025-02-11 | — | — | US | disclosed |
| US-12122755-B2 | Methods for producing nitroso compound and quinoxaline compound | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2024-10-22 | — | — | US | disclosed |
| US-4224290-A | RECOVERING ORGANIC HYPOHALITE AND ALKALI METAL HALIDE FROM AQUEOUS ALKALINE EARTH HALIDE AND HYPOHALITE | OLIN CORPORATION (US) | 1980-09-23 | — | — | US | disclosed |
| US-4196140-A | Recovery of waste streams containing recoverable chlorine | OLIN CORPORATION (US) | 1980-04-01 | — | — | US | disclosed |
| US-4177115-A | ELECTROLYSIS OF BRINE AND ALCOHOL | OLIN CORPORATION (US) | 1979-12-04 | — | — | US | disclosed |
| US-4111917-A | POLYURETHANES | W. R. GRACE & CO. (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12122755-B2 | Methods for producing nitroso compound and quinoxaline compound | ADH1C, NOXO1, NOX1 | CYP2C19 148/4885CYP1A2 71/4885CYP2C9 30/4885 |
| US-12221458-B2 | Organic borate-based catalyst, method for preparing isobutene oligomer using the same and isobutene oligomer prepared thereby | OXER1, ORC3, OSBP | CYP2C19 1829/4885CYP1A2 982/4885CYP2C9 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.